Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.
Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany.
Int Urol Nephrol. 2022 Jan;54(1):71-79. doi: 10.1007/s11255-021-03073-5. Epub 2021 Nov 24.
To compare clinical outcome and quality of life (QoL) in octogenarian patients with muscle-invasive urothelial carcinoma (MIBC) either treated by radical cystectomy (RC) or transurethral resection of the tumor (TURBT).
We identified octogenarian patients with MIBC in our institutions since 2005. Clinical treatment outcomes and QoL were analyzed. Uni- and multivariable Cox regression analyses, two-tailed Wilcoxon test, Mann-Whitney test and Fisher's exact test were assessed as appropriate. QoL was evaluated using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire.
143 patients were identified (RC: 51 cases, TURBT: 92 cases). Mean follow-up was 14 months (0-100 months). Median overall survival (OS) was 12 months in the RC group and 7 months in the TURBT group. TURBT and low preoperative hemoglobin were independent risk factors for reduced cancer-specific survival (CSS) (TURBT: p = 0.019, Hb: p = 0.008) and OS (TURBT: p = 0.026, Hb: p = 0.013) in multivariable analyses. Baseline QoL was low throughout the whole cohort. There was no difference in baseline FACT-G scoring comparing RC and TURBT (FACT-G total score (median): RC 43.7/108 vs. TURBT 44.0/108, p = 0.7144). Increased FACT-G questionnaire scoring was assessed for RC patients (median percentage score change RC 22.9%, TURBT 2.3%, p < 0.0001).
RC and TURBT are feasible treatment options for MIBC in octogenarian patients. In our cohort, RC was associated with increased CSS, OS and QoL. QoL in general was low throughout the whole cohort. Interdisciplinary decision-making has to be improved for these critically ill patients.
比较行根治性膀胱切除术(RC)或经尿道肿瘤切除术(TURBT)的 80 岁以上肌层浸润性膀胱癌(MIBC)患者的临床结局和生活质量(QoL)。
我们在机构中确定了自 2005 年以来 80 岁以上患有 MIBC 的患者。分析了临床治疗结果和 QoL。使用单变量和多变量 Cox 回归分析、双侧 Wilcoxon 检验、Mann-Whitney 检验和 Fisher 精确检验进行评估。使用 FACT-G(癌症治疗功能评估-一般)问卷评估 QoL。
共确定了 143 例患者(RC:51 例,TURBT:92 例)。中位随访时间为 14 个月(0-100 个月)。RC 组的中位总生存期(OS)为 12 个月,TURBT 组为 7 个月。多变量分析显示,TURBT 和术前低血红蛋白是降低癌症特异性生存率(CSS)(TURBT:p=0.019,Hb:p=0.008)和 OS(TURBT:p=0.026,Hb:p=0.013)的独立危险因素。整个队列的基线 QoL 均较低。RC 和 TURBT 组的基线 FACT-G 评分无差异(FACT-G 总分(中位数):RC 43.7/108 vs. TURBT 44.0/108,p=0.7144)。RC 患者的 FACT-G 问卷评分增加(RC 组中位数百分比评分变化 22.9%,TURBT 组 2.3%,p<0.0001)。
RC 和 TURBT 是 80 岁以上 MIBC 患者可行的治疗选择。在我们的队列中,RC 与增加的 CSS、OS 和 QoL 相关。整个队列的 QoL 普遍较低。需要改善这些危重患者的多学科决策。